SV2002000440A - Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb - Google Patents

Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb

Info

Publication number
SV2002000440A
SV2002000440A SV2001000440A SV2001000440A SV2002000440A SV 2002000440 A SV2002000440 A SV 2002000440A SV 2001000440 A SV2001000440 A SV 2001000440A SV 2001000440 A SV2001000440 A SV 2001000440A SV 2002000440 A SV2002000440 A SV 2002000440A
Authority
SV
El Salvador
Prior art keywords
disease
inhibitor
procedure
treatment
cognitive
Prior art date
Application number
SV2001000440A
Other languages
English (en)
Inventor
Jotham Wadsworth Coe
Edmund Patrick Harrigan
Brian Thomas O'neill
Steven Bradley Sands
Eric Jacob Watsky
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2002000440A publication Critical patent/SV2002000440A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE TRATAMIENTO DE ENFERMEDADES DE DISFUNSION COGNITIVA EN UN MAMIFERO, QUE COMPRENDE LA ADMINISTRACION DE UN AGONISTA PARCIAL DEL RECEPTOR DE NICOTINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; Y UN INHIBIDOR DE ACETILCOLINESTRA, UN INHIBIDOR DE BUTILCOLINESTERASA, UN AGENTE ENTROGENICO, UN MODULADOR SELECTIVO DEL RECEPTOR DE ESTREOGENOS O UN AGONISTA MUSCARINICO, O UNA SAL FARMACEUTICAMENTE ACEPTABLE. EL AGONISTA PARCIAL DEL RECEPTOR DE NICOTINA Y EL INHIBIDOR DE ACETILCOLINESTERASA, EL INHIBIDOR DE BUTILCOLINESTERASA, EL ESTROGENO, EL MODULADOR SELECTIVO DEL RECEPTOR DE ESTROGENOS O EN ANTAGONISTA MUSCARINICO ESTAN PRESENTES EN CANTIDADES QUE HACEN A LA COMPOSICION EFICAZ EN LA POTENCIACION DE LA COGNICION O EN EL TRATAMIENTO DE ENFERMEDADES DE DISFUNCION COGNITIVA QUE INCLUYEN, PERO SIN LIMITACION, LA ENFERMEDAD DE ALZHEIMER, DETERIORO COGNITIVO LEVE, DISMINUCION COGNITIVA RELACIONADAD CON LA EDAD, DEMENCIA VASCULAR, DEMENCIA POR ENFERMEDAD DE PARKINSON, ENFERMEDAD DE HUNTINGTON, APOPLEJIA, TBI, DEMENCIA ASOCIADA CON EL SIDA Y ESQUIZOFRENIA. TAMBIEN SE DESCRIBE EL PROCEDIMIENTO DE USO DE ESTAS COMPOSICIONES
SV2001000440A 2000-05-09 2001-05-08 Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb SV2002000440A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20279900P 2000-05-09 2000-05-09

Publications (1)

Publication Number Publication Date
SV2002000440A true SV2002000440A (es) 2002-10-24

Family

ID=22751325

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000440A SV2002000440A (es) 2000-05-09 2001-05-08 Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb

Country Status (16)

Country Link
US (2) US20010036949A1 (es)
EP (1) EP1280554A2 (es)
JP (1) JP2003532670A (es)
AR (1) AR028426A1 (es)
AU (1) AU2001248699A1 (es)
BR (1) BR0110487A (es)
CA (1) CA2409720A1 (es)
EC (1) ECSP014065A (es)
GT (1) GT200100075A (es)
MX (1) MXPA02011051A (es)
PA (1) PA8516701A1 (es)
PE (1) PE20011256A1 (es)
SV (1) SV2002000440A (es)
TN (1) TNSN01068A1 (es)
UY (1) UY26693A1 (es)
WO (1) WO2001085145A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
ES2275670T3 (es) 2000-03-03 2007-06-16 EISAI R&D MANAGEMENT CO., LTD. Metodos novedosos utilizando inhibidores de colinesterasa.
PL366657A1 (en) * 2001-04-20 2005-02-07 Pfizer Products Inc. Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
IL160208A0 (en) * 2001-08-31 2004-07-25 Neurochem Int Ltd Amidine derivatives for treating amyloidosis
US20040092427A1 (en) * 2002-09-25 2004-05-13 Anil Gulati Method and composition for treating alzheimer's disease and dementias of vascular origin
US8030300B2 (en) * 2003-06-10 2011-10-04 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US8299062B2 (en) * 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
JP4976134B2 (ja) 2003-10-01 2012-07-18 アドラー コーポレーション スピロ環複素環誘導体及びそれらを使用する方法
US20060019938A1 (en) * 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
WO2005112908A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function
EP1749017A2 (en) * 2004-05-27 2007-02-07 MIGENIX Corp. Compounds and methods for cytoprotection
EP2258358A3 (en) * 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
GB0607952D0 (en) * 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
CN101534819A (zh) 2006-09-12 2009-09-16 阿得罗公司 含氮的螺环化合物用于增强认知功能的应用
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
CN102905532A (zh) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US8846061B1 (en) 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
US8349376B1 (en) 2011-03-08 2013-01-08 Bezzek Mark S Anti-dementia regimen
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2012142039A1 (en) * 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders

Also Published As

Publication number Publication date
JP2003532670A (ja) 2003-11-05
PE20011256A1 (es) 2001-12-29
MXPA02011051A (es) 2003-03-10
WO2001085145A8 (en) 2001-12-13
US20010036949A1 (en) 2001-11-01
TNSN01068A1 (fr) 2005-11-10
EP1280554A2 (en) 2003-02-05
CA2409720A1 (en) 2001-11-15
WO2001085145A3 (en) 2002-06-13
GT200100075A (es) 2001-12-31
ECSP014065A (es) 2003-01-13
PA8516701A1 (es) 2002-09-17
AU2001248699A1 (en) 2001-11-20
AR028426A1 (es) 2003-05-07
US20030130303A1 (en) 2003-07-10
UY26693A1 (es) 2001-12-28
WO2001085145A2 (en) 2001-11-15
BR0110487A (pt) 2003-04-01

Similar Documents

Publication Publication Date Title
SV2002000440A (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb
CR7059A (es) USO DE AGONISTAS INVERSOS DE GABAa EN COMBINACION CON AGONISTAS PARCIALES DEL RECEPTOR DE NICOTINA, ESTROGENOS, MODULADORES SELECTIVOS DE ESTROGENOS O VITAMINA E PARA EL TRAMIENTO DE TRASTORNOS COGNITIVOS
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
BG66085B1 (bg) Фенилаланинови производни
HUP0301892A2 (hu) Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk
PA8591701A1 (es) Derivados de pirrolopirimidina
HUP0101543A2 (hu) Női szexuális zavarok kezelésére szolgáló gyógyszerkészítmények
MA28009A1 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
BR0113980A (pt) Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores de função de receptor de hormÈnio nuclear
HK1113970A1 (en) Formulations for injection of catecholic butanes, including ndga compounds, into animals
TNSN97044A1 (fr) Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.
BR0313148A (pt) Formulações de liberação controlada compreendendo lamotrigina
ITFI20030058A1 (it) Formulazioni farmaceutiche contenenti tiazolidinedioni
SE0102055D0 (sv) New Compounds
TNSN01175A1 (fr) Derives de piperidines antagonistes selectives de sous- types de recepteurs de nmda, et compositions les contenant.
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
SE0002729D0 (sv) Novel compound form
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
ES2113533T3 (es) Composiciones farmaceuticas de alquilsulfonamidas agonistas de 5-ht1 para administracion rectal.
MXPA05011476A (es) Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2.
GEP20043377B (en) Pharmaceutical Complex
DE50202865D1 (de) Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
BR0005319A (pt) Tratamento combinado para depressão e ansiedade

Legal Events

Date Code Title Description
FC Refusal